ModifiedUnitedHealthcarePolicy CS016NJ.M

Chelation Therapy

This New Jersey–specific UnitedHealthcare medical policy governs clinical coverage and evidence-based indications for chelation therapy, describing when chelation is medically necessary (heavy metal overload) and when it is considered unproven or not medically necessary (non-overload conditions and mercury from dental amalgams). It applies to providers and members in New Jersey.

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy

Policy CodePolicy CS016NJ.M

Change TypeMaterial coverage rationale update (clarified overload indications as proven and medically necessary)

Effective Date08/01/2025

Next Review DateN/A

Key ActionWhen requesting chelation for non‑FDA‑approved indications, submit prior authorization with diagnostic testing, prior therapies tried, and supporting evidence.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Chelation Therapy for Non-Overload Conditions (for New Jersey Only)' to 'Chelation Therapy'.

Coverage rationale language was revised to state that chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary.

Clinical Evidence and References sections were updated to reflect the most current information.

FDA‑approved/overloadIndications acknowledged

Not medically necessaryNon‑overload uses

NMN

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Dental amalgam mercury

Multiple trialsEvidence — iron agents

1,708TACT participants

08/01/2025Revision date

Coverage Criteria for Chelation Therapy

Chelation for heavy metal toxicity and overload

Covered when ALL of the following are met:

Heavy metal overload indication: Objective diagnosis of heavy metal toxicity or overload (e.g., iron, copper, lead, aluminum) with appropriate diagnostic workup and reference values documentedN/A

Chelation is established and medically necessary for these conditions.

Non-overload and dental amalgam mercury

Not medically necessary or unproven when ANY of the following apply:

Non-overload chronic/progressive diseases: Chelation used to treat chronic, progressive diseases where heavy metal overload has not been demonstrated (e.g., cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer’s disease, autism, Parkinson’s disease, rheumatoid arthritis, and many other listed conditions)N/A

Considered unproven and not medically necessary due to insufficient evidence of efficacy.

Mercury from dental amalgam: Chelation therapy to treat alleged mercury 'toxicity' from dental amalgam fillingsN/A

Not medically necessary; amalgam fillings are not shown to cause harm except in rare allergy cases.

Indicated use: Documented metal intoxication

Covered when ALL of the following are met for documented metal intoxication:

Documented metal intoxication: There is a documented metal intoxication diagnosis confirmed using validated tests on appropriate biological samples (e.g., blood lead level, ferritin/iron studies) and clinical correlation.validated diagnostic test result

Supported by AAFP and ACMT position statements; diagnostic workup must include appropriate testing methods and reference values.

Appropriate indication and regimen: Chelation agent, dose, and route are appropriate for the specific metal intoxication per FDA-approved indications and toxicology guidance.agent-specific approved use

Use should align with FDA‑approved indications and recognized drug compendia.

Monitoring and safety: Monitoring plans for known chelation risks (e.g., renal function, electrolytes, signs of hypocalcemia) are documented and available.

Not covered / investigational indications

Not covered / considered investigational for the following indications due to insufficient evidence or lack of demonstrated benefit:

Autism Spectrum Disorder: Use of chelation (oral or IV) to treat ASD symptoms—no evidence of benefit and potential for serious adverse events (hypocalcemia, renal impairment, death).no proven clinical benefit

Cochrane and other reviews found no supportive clinical trial evidence and noted safety concerns.

Cardiovascular disease (general): Chelation (EDTA infusions) has not demonstrated consistent reduction in cardiovascular events across trials and systematic reviews; not approved for preventing or treating CVD by guideline bodies.no consistent benefit for ASCVD

Cochrane and recent RCTs (including a 2024 EDTA trial) did not show consistent clinical benefit.

Peripheral vascular disease / PAD: Evidence does not show significant improvements in ankle–brachial index or walking distance; trials limited and inconsistent.

Exploratory subgroup findings

Exploratory findings (not sufficient for coverage):

Diabetes with prior MI subgroup (TACT) signal: Post-hoc analyses suggested reduced cardiovascular events among individuals with diabetes in TACT; results are hypothesis-generating and require replication in targeted trials.post-hoc subgroup signal

Authors and reviewers recommend further research before clinical adoption.

Anterior MI subgroup signal: Post-hoc analysis suggested benefit for those with prior anterior MI, but findings are exploratory with potential confounding and require confirmation.post-hoc subgroup signal

Analyses were post hoc and authors caution these findings be considered hypothesis-generating.

Lead level reduction without clinical benefit: Trials show EDTA can reduce blood lead levels, but reductions did not translate into lower CVD events in a 2024 trial of post-MI diabetic patients.

Coverage stance and guideline‑based limitations

Coverage stance and key clinical limitations from this document portion:

FDA‑approved indications: Chelation therapy using FDA‑approved chelating agents is recognized as approved when used for metal poisoning or iron overload as listed in approved drug compendia.FDA-approved indication

Use should be limited to FDA‑approved indications and referenced compendia.

Not recommended indications: Chelation should not be used to attempt to improve angina or exercise tolerance in stable ischemic heart disease (per Canadian Cardiovascular Society) or to treat core symptoms of autism (per NICE); FDA also warns that chelating agents are not approved to treat or cure autism and has warned companies making such claims.guideline/recommendation based

Guideline bodies and FDA statements cited in the policy advise against these uses.

Chelation therapy is reserved for situations where objective heavy metal toxicity or overload has been demonstrated. The policy excludes use of chelating agents for a broad set of non‑overload conditions—including cardiovascular disease, diabetes, cancer, neurodegenerative disorders, autism spectrum disorder, and other chronic/progressive diseases—because well‑designed, peer‑reviewed studies do not support clinical benefit for these indications. When considering chelation, documentation must establish an appropriate diagnosis using validated testing and reference values consistent with accepted toxicology practice.

Chelation therapy intended to treat alleged mercury ‘toxicity’ from dental amalgam fillings is specifically excluded. The available evidence does not demonstrate that dental amalgam restorations cause clinically important mercury toxicity in the general population, and chelation for routine treatment of autism, cardiovascular disease, neurodegenerative diseases, or dental amalgam‑related mercury exposure is considered unproven and not medically necessary.

High‑quality systematic reviews and randomized trials have failed to demonstrate benefit of chelation for autism or for improving cardiovascular outcomes in stable ischemic heart disease. A Cochrane review found no evidence that pharmaceutical chelation improves core ASD symptoms and highlighted safety concerns, while pooled cardiovascular trial data have not shown consistent reductions in mortality, MI, angina, or functional measures that would support routine use in stable IHD or post‑MI care.

Based on the totality of evidence summarized in this policy, chelation therapy for non‑overload conditions and for alleged mercury toxicity from dental amalgam fillings is unproven and not medically necessary in the absence of documented metal intoxication confirmed by validated testing.

Chelation therapy is considered not medically necessary for treatment of autism spectrum disorder, for routine use in stable ischemic heart disease, and for routine post‑myocardial infarction care. A Cochrane review of ASD trials found no evidence of benefit and noted reports of serious adverse events; large cardiovascular trials and systematic reviews (including the TACT trial and subsequent pooled analyses) have not provided consistent, reproducible evidence to support clinical benefit outside of exploratory subgroup signals.

Major professional organizations and regulatory bodies cited in the literature do not support chelation for autism or to improve symptoms or exercise tolerance in stable IHD. The American College of Medical Toxicology, Canadian Cardiovascular Society, NICE, and the FDA note that chelation should be limited to documented metal intoxication and warn against its use for autism or routine cardiovascular indications.

Applicable Codes and Measurement Endpoints

Applicable HCPCS Codes (reference list)HCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Treatment response / monitoring measures

Serum ferritinUsed as a primary biochemical endpoint to assess iron chelation efficacy and correlated with compliance and outcomes in ICT studies.

Liver iron concentration (LIC)Measured to evaluate tissue iron burden and response to iron chelation therapy in trials and observational studies.

Cardiac MRI T2*/R2*Used to quantify cardiac iron and monitor changes with iron chelation; included as an outcome in multiple iron‑chelation studies.

Provider Actions, Prior Authorization, and Documentation

Billing Rule

Code List and Prior Authorization Implications

Code lists below are provided for reference; inclusion does not guarantee coverage. Certain injectable/infusion codes for chelating agents and home infusion services may require prior authorization per state or contractual rules. Verify benefit coverage and PA requirements prior to scheduling.

J0470 — Injection, dimercaprol, per 100 mg
J0600 — Injection, edetate calcium disodium, up to 1000 mg
J0895 — Injection, deferoxamine mesylate, 500 mg
J3520 — Edetate disodium, per 150 mg
J3490 — Unclassified drugs (may require coding clarification)
S9355 — Home infusion therapy, chelation therapy; per diem (drugs and nursing visits coded separately)
M0300 — IV chelation therapy (chemical endarterectomy)
J8499 — Prescription drug, oral, nonchemotherapeutic, NOS
*Codes marked with an asterisk may not be on the State of New Jersey Medicaid Fee Schedule and may not be covered by NJ Medicaid

Background and Evidence Context

Chelation therapy works by administering agents that bind metal ions and facilitate their excretion; agent selection, dose, and route are determined by the specific metal and clinical circumstance. When heavy metal overload is objectively documented (for example, lead poisoning or iron overload), chelation is an established, medically necessary intervention with monitoring for known risks such as renal impairment, electrolyte disturbances, and essential mineral depletion.

Definitions and Agent Descriptions

Chelation therapy — definition, agents, and routes

DefinitionAdministration of molecules (natural or synthetic) that bind specific metal toxins to promote excretion; agent, route, method, and site vary by agent and toxicity level.

Common agentsIncludes parenteral and oral chelators selected based on the target metal (examples include EDTA, deferoxamine, deferasirox, deferiprone, DMSA).

Routes of administrationRoutes vary by agent and indication and include intravenous infusion (e.g., EDTA, deferoxamine), intramuscular (e.g., dimercaprol), and oral (e.g., DMSA, deferasirox, deferiprone).

Non‑overload conditions — definition and scope

DefinitionConditions where acute or chronic heavy metal toxicity has not been demonstrated and chelation is hypothesized (but not proven) to provide benefit, such as cardiovascular disease, diabetes, cancer, neurodegenerative disorders, and autism spectrum disorder.

Policy Revision History

2025-08-01Title changeLatest

Policy title changed from 'Chelation Therapy for Non-Overload Conditions (for New Jersey Only)' to 'Chelation Therapy'.

2025-08-01Coverage rationale update

Coverage rationale revised to state that chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary.

2025-08-01Supporting information updated

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy

Policy CodePolicy CS016NJ.M

Change TypeMaterial coverage rationale update (clarified overload indications as proven and medically necessary)

Effective Date08/01/2025

Next Review DateN/A

Key ActionWhen requesting chelation for non‑FDA‑approved indications, submit prior authorization with diagnostic testing, prior therapies tried, and supporting evidence.

SourceLink

On This Page

laboratory monitoring as clinically indicated

ACMT highlights potential significant adverse effects; monitoring must be documented.

no significant functional improvement

Meta-analyses report low-certainty evidence and no consistent functional benefit.

Parkinson disease: Small randomized trials of brain iron chelation (DFP) showed target engagement but no conclusive patient-centered benefit; larger trials needed.insufficient evidence

Small sample sizes and non-significant clinical outcomes limit conclusions.

Mercury from dental amalgam: No high-quality evidence supports chelation for adverse outcomes attributed to dental amalgam; overall evidence does not support harm from amalgam restorations that would warrant chelation.insufficient causal evidence

Systematic reviews and RCTs show no demonstrated harm from dental amalgam restorations.

biomarker improvement only

Biomarker improvements observed without concordant clinical outcome benefits.

Prior Authorization

Prior Authorization for Off-Label Chelation

Prior authorization is required for chelation therapy when used for indications that are off-label or not consistent with documented metal intoxication/overload. Requests for chelation to treat cardiovascular disease, neurodevelopmental disorders (including autism), chronic non‑overload conditions, or to remove dental amalgam mercury without validated evidence of intoxication are subject to denial unless clear, validated diagnostic documentation and justification are provided.

Prior Authorization

PA Aligns with Coverage Rationale

Prior authorization requirements will be applied in a manner consistent with the coverage rationale: medically necessary coverage is limited to documented metal intoxication or overload (and FDA‑approved/compendium‑supported indications); PA determinations should reflect differentiation between overload/poisoning indications (may be approved) versus non‑overload or investigational indications (generally not approved).

Denial Risk

Denial Risk for Non‑Approved/Unsupported Indications

Requests for chelation for non‑approved or unsupported indications (for example: autism, routine prevention or treatment of cardiovascular disease/atherosclerosis, improvement of angina or exercise tolerance in stable IHD without validated metal intoxication, or for removal of dental amalgam mercury absent documented intoxication) carry a high denial risk.

Documentation Required

Diagnostic Documentation Requirements

Diagnostic workup documentation must demonstrate heavy metal overload or validated intoxication using appropriate biological samples and recognized reference values. Documentation should include patient history, exposure assessment, laboratory/test type and method, numeric results with reference ranges, and any confirmatory testing. Empiric or unvalidated testing alone is insufficient.

Document patient history and exposure sources
Provide validated test type (e.g., blood, urine, hair where appropriate) and laboratory methods
Include numeric results with laboratory reference ranges and interpretation
Include any confirmatory testing or repeat measurements if performed

Documentation Required

Documentation for Metal Intoxication

For suspected metal intoxication, require validated diagnostic testing on appropriate biological samples (blood, urine, or tissue as clinically indicated) and interpretation by a qualified clinician or toxicologist. Laboratory reports should reference testing methodology and laboratories’ accreditation when available.

Validated testing (e.g., blood lead level, serum ferritin with LIC assessment by R2*/T2* MRI for iron overload)
Appropriate sample type for the suspected metal
Laboratory methodology and reference ranges
Specialist consultation or toxicology confirmation when indicated

Documentation Required

Document Indication and Supporting Compendium Reference

Clinical indication must be explicitly documented in the PA request and supported by references to FDA‑approved indications or recognized drug compendia where applicable. When approval is sought for an off‑label use, provide supporting clinical literature and rationale demonstrating why standard treatments are not appropriate.

State the specific indication and clinical findings
Cite FDA‑approved labeling or compendium references for the chelating agent used
If off‑label, include peer‑reviewed evidence and clinical rationale for use

Step Therapy

Step Therapy Not Specified — Clinical Considerations

This policy does not specify a step‑therapy sequence or preferred chelating agent. When treating conditions such as iron overload, guideline‑based standard therapies (including established chelators with labeled indications) should be considered and documented before alternative approaches are pursued; clinical justification is required if standard options are declined or contraindicated.

Note

Use of Decision Support Tools

UnitedHealthcare may use external decision support tools (for example, InterQual® criteria) or other clinical review resources when assessing medical necessity for chelation therapy. Providers should ensure PA submissions include the documentation elements and evidence that such tools require to avoid delays.

Be prepared to supply full diagnostic reports, laboratory methodologies, and compendium references for reviewer assessment
Clinical notes describing prior therapies, contraindications, or intolerance when applicable

ScopeIncludes proposed uses like treatment of CVD, RA, cancer, diabetes, Alzheimer’s, Parkinson’s, ASD, and other chronic/progressive diseases where evidence does not demonstrate metal overload.

Evidence summaryWell-designed peer-reviewed studies do not support chelation for these non-overload conditions; risks have been reported (e.g., hypocalcemia, renal impairment).

EDTA‑based chelation — common infusion regimens

Typical regimen in trialsInfusion-based EDTA regimens commonly studied as 40 weekly infusions of an EDTA-based solution (e.g., Na2EDTA) in cardiovascular chelation trials.

Trial contextRegimen evaluated in large cardiovascular trials such as TACT and subsequent multicenter EDTA trials enrolling participants with prior MI (some subsets with diabetes).

Measured effectsStudies reported reduction in blood lead levels with EDTA after 40 infusions but no consistent reduction in composite cardiovascular events in broader trial populations.

Other chelators — oral agents and study contexts

Oral DMSADimercaptosuccinic acid (DMSA) has been studied orally in trials (including pediatric ASD trials) to increase metal excretion but showed no evidence of clinical benefit for ASD and has safety concerns.

Deferasirox (DFX)An oral iron chelator evaluated in iron-overload populations (e.g., MDS, thalassemia) and shown to prolong event‑free survival in TELESTO for iron‑overloaded MDS patients.

Deferiprone (DFP)An oral iron chelator studied for brain iron reduction in Parkinson disease trials; demonstrated target engagement but no conclusive patient‑centered benefit in small trials.

FDA‑approved chelating agents — approvals and limitations

FDA‑approved usesFDA approves chelating agents when used for metal poisoning or iron overload; use is limited to FDA‑approved indications as listed in recognized drug compendia.

Reference guidanceApproved uses and prescribing information should be verified in compendia such as AHFS or DrugDex and the FDA resource provided in the policy.

Coverage noteFDA approval is informational and not by itself a basis for coverage decisions; coverage follows policy criteria and compendia references.

Non‑overload chelation — clarification of scope and concerns

DefinitionUse of chelation therapy to treat conditions other than metal poisoning or iron overload (e.g., autism, stable ischemic heart disease) where heavy metal overload has not been demonstrated.

Clinical guidanceMajor guidelines (e.g., NICE on autism) do not recommend chelation for core symptoms of autism; evidence is insufficient to support these non‑overload uses.

Safety considerationsReported serious adverse events (hypocalcemia, renal impairment, death) have been associated with off‑label chelation in non‑overload settings, underscoring lack of proven benefit and potential harm.

Clinical Evidence and References sections were updated and the prior policy version CS016NJ.L was archived.